Overview

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

Status:
Terminated

Trial end date:
2020-11-05

Target enrollment:

Participant gender:

Summary

This trial will evaluate safety, tolerability, and efficacy of letetresgene autoleucel (GSK3377794) with or without pembrolizumab in participants with relapsed and refractory multiple myeloma.

Phase:

Phase 1

Details

Lead Sponsor:

Adaptimmune
GlaxoSmithKline

Collaborators:

GlaxoSmithKline
Merck Sharp & Dohme Corp.

Treatments:

Cyclophosphamide
Fludarabine
Pembrolizumab